Jake Morgan
Profiles

Jake Roberts Morgan, PhD

Research Assistant Professor, Health Law, Policy & Management - Boston University School of Public Health

Biography

Jake Morgan, PhD, is a health services researcher specializing in using real-world data to inform evidence-based policy, update clinical guidelines, and improve patient access to and quality of care.

His work is focused on the opioid overdose epidemic and how to best support patients by promoting access and retention to medications for opioid use disorder. His work on the comparative effectiveness of medications for opioid use disorder has been cited in a call for research by the director of the National Institute on Drug Abuse Nora Volkow and he has a history of collaboration with Massachusetts Department of Public Health to evaluate and inform addiction treatment services. His work has consistently reinforced the importance of patient choice when it comes to treatment for opioid use disorder and has documented the effects of policies that usurp this choice through onerous requirements for treatment, restricting access to vulnerable populations such as individuals who are incarcerated, and cost-sharing schemes that disincentivize treatment. As an applied health economist with extensive experience in statistical, econometric, and simulation modeling approaches, Dr. Morgan frequently works alongside clinical researchers to highlight (and cost) the best treatment interventions for patients. He is currently involved with the Health Economics core of the The HEALing Communities Study; the Prevention and Rescue Of Fentanyl and Other Opioid Overdoses Using Optimized Naloxone Distribution Strategies (PROFOUND) study; the Researching Effective Strategies to Prevent Opioid Death (RESPOND) simulation model, and; The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for HCV trial.

Dr. Morgan works closely with The Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV (CHERISH) as a member of the Population Data and Modeling Core and is the primary representative for Boston University School of Public Health. The Center’s mission is to develop and disseminate health economic research on healthcare utilization, health outcomes, and health-related behaviors to inform policy to improve care for individuals with substance use disorder, HIV, and HCV. To that end, CHERISH offers resources and consultations to support this type of research for trainees and investigators at any stage. Please see https://cherishresearch.org/ or contact Dr. Morgan to learn more.

Education

  • Boston University, PhD Field of Study: Health Services Research
  • Montana State University, MS Field of Study: Economics
  • Hillsdale College, BS Field of Study: Economics/Mathematics

Publications

  • Published on 5/1/2024

    Zang X, Skinner A, Krieger MS, Behrends CN, Park JN, Green TC, Walley AY, Morgan JR, Linas BP, Yedinak JL, Schackman BR, Marshall BDL. Evaluation of Strategies to Enhance Community-Based Naloxone Distribution Supported by an Opioid Settlement. JAMA Netw Open. 2024 May 01; 7(5):e2413861. PMID: 38814644.

    Read At: PubMed
  • Published on 4/9/2024

    Freibott CE, Jalali A, Murphy SM, Walley AY, Linas BP, Jeng PJ, Bratberg J, Marshall BDL, Zang X, Green TC, Morgan JR. The association between naloxone claims and proportion of independent vs. chain pharmacies: A longitudinal analysis of naloxone claims in the US. J Am Pharm Assoc (2003). 2024 Apr 09; 102093. PMID: 38604474.

    Read At: PubMed
  • Published on 4/5/2024

    Ellison JE, Brown-Podgorski BL, Morgan JR. Changes in Permanent Contraception Procedures Among Young Adults Following the Dobbs Decision. JAMA Health Forum. 2024 Apr 05; 5(4):e240424. PMID: 38607642.

    Read At: PubMed
  • Published on 4/3/2024

    Morgan JR, Leech AA. Commentary on Schmidt et al.: Informed patient preference and prioritizing access to medications for opioid use disorder for pregnant individuals. Addiction. 2024 Jun; 119(6):1123-1124. PMID: 38570825.

    Read At: PubMed
  • Published on 12/18/2023

    McCann NC, LaRochelle MR, Morgan JR. Out-of-pocket spending and health care utilization associated with initiation of different medications for opioid use disorder: Findings from a national commercially insured cohort. J Subst Use Addict Treat. 2024 Apr; 159:209281. PMID: 38122988.

    Read At: PubMed
  • Published on 10/28/2023

    Morgan JR, Assoumou SA. The limits of innovation: Directly addressing known challenges is necessary to improve the real-world experience of novel medications for opioid use disorder. Acad Emerg Med. 2023 Dec; 30(12):1285-1287. PMID: 37793818.

    Read At: PubMed
  • Published on 10/4/2023

    Park TW, Baul TD, Morgan JR, Wilens TE, Yule AM. Trends in Attention-Deficit Hyperactivity Disorder Diagnosis and Pharmacotherapy Among Adults With Opioid Use Disorder. Psychiatr Serv. 2024 Mar 01; 75(3):214-220. PMID: 37789727.

    Read At: PubMed
  • Published on 9/26/2023

    Tin Y, Castry M, Bowers-Sword R, Shantharam S, Aldridge A, Zarkin GA, Starbird L, Linas BP, Barocas JA, Morgan JR. Establishing a Protocol for Determining the Costs of an Integrated Set of Evidence-based Practices Aimed at Reducing Opioid Overdose Deaths. J Addict Med. 2024 Jan-Feb 01; 18(1):13-18. PMID: 37768777.

    Read At: PubMed
  • Published on 9/5/2023

    Flam-Ross JM, Marsh E, Weitz M, Savinkina A, Schackman BR, Wang J, Madushani RWMA, Morgan JR, Barocas JA, Walley AY, Chrysanthopoulou SA, Linas BP, Assoumou SA. Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder. JAMA Netw Open. 2023 Sep 05; 6(9):e2329583. PMID: 37703018.

    Read At: PubMed
  • Published on 9/1/2023

    Leech AA, McNeer E, Roberts AW, Dusetzina SB, Lai P, Morgan JR, Patrick SW. Buprenorphine Out-of-Pocket Costs and Discontinuation in Privately Insured Adults With Opioid Use Disorder. JAMA Intern Med. 2023 Sep 01; 183(9):1023-1026. PMID: 37548972.

    Read At: PubMed

News & In the Media